580 related articles for article (PubMed ID: 23731216)
1. Discovery and development of orexin receptor antagonists as therapeutics for insomnia.
Winrow CJ; Renger JJ
Br J Pharmacol; 2014 Jan; 171(2):283-93. PubMed ID: 23731216
[TBL] [Abstract][Full Text] [Related]
2. Orexin in sleep, addiction and more: is the perfect insomnia drug at hand?
Hoyer D; Jacobson LH
Neuropeptides; 2013 Dec; 47(6):477-88. PubMed ID: 24215799
[TBL] [Abstract][Full Text] [Related]
3. Almorexant, a dual orexin receptor antagonist for the treatment of insomnia.
Neubauer DN
Curr Opin Investig Drugs; 2010 Jan; 11(1):101-10. PubMed ID: 20047164
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of almorexant in adult chronic insomnia: a randomized placebo-controlled trial with an active reference.
Black J; Pillar G; Hedner J; Polo O; Berkani O; Mangialaio S; Hmissi A; Zammit G; Hajak G
Sleep Med; 2017 Aug; 36():86-94. PubMed ID: 28735928
[TBL] [Abstract][Full Text] [Related]
5. Dual orexin receptor antagonists - promising agents in the treatment of sleep disorders.
Pałasz A; Lapray D; Peyron C; Rojczyk-Gołębiewska E; Skowronek R; Markowski G; Czajkowska B; Krzystanek M; Wiaderkiewicz R
Int J Neuropsychopharmacol; 2014 Jan; 17(1):157-68. PubMed ID: 23702225
[TBL] [Abstract][Full Text] [Related]
6. Emerging role of orexin antagonists in insomnia therapeutics: An update on SORAs and DORAs.
Kumar A; Chanana P; Choudhary S
Pharmacol Rep; 2016 Apr; 68(2):231-42. PubMed ID: 26922522
[TBL] [Abstract][Full Text] [Related]
7. Preclinical in vivo characterization of lemborexant (E2006), a novel dual orexin receptor antagonist for sleep/wake regulation.
Beuckmann CT; Ueno T; Nakagawa M; Suzuki M; Akasofu S
Sleep; 2019 Jun; 42(6):. PubMed ID: 30923834
[TBL] [Abstract][Full Text] [Related]
8. Differential sleep-promoting effects of dual orexin receptor antagonists and GABAA receptor modulators.
Gotter AL; Garson SL; Stevens J; Munden RL; Fox SV; Tannenbaum PL; Yao L; Kuduk SD; McDonald T; Uslaner JM; Tye SJ; Coleman PJ; Winrow CJ; Renger JJ
BMC Neurosci; 2014 Sep; 15():109. PubMed ID: 25242351
[TBL] [Abstract][Full Text] [Related]
9. Orexin OX
Jacobson LH; Chen S; Mir S; Hoyer D
Curr Top Behav Neurosci; 2017; 33():105-136. PubMed ID: 27909987
[TBL] [Abstract][Full Text] [Related]
10. Assessment of the abuse liability of a dual orexin receptor antagonist: a crossover study of almorexant and zolpidem in recreational drug users.
Cruz HG; Hoever P; Chakraborty B; Schoedel K; Sellers EM; Dingemanse J
CNS Drugs; 2014 Apr; 28(4):361-72. PubMed ID: 24627301
[TBL] [Abstract][Full Text] [Related]
11. Examining the role of endogenous orexins in hypothalamus-pituitary-adrenal axis endocrine function using transient dual orexin receptor antagonism in the rat.
Steiner MA; Sciarretta C; Brisbare-Roch C; Strasser DS; Studer R; Jenck F
Psychoneuroendocrinology; 2013 Apr; 38(4):560-71. PubMed ID: 22917622
[TBL] [Abstract][Full Text] [Related]
12. Hypocretin antagonists in insomnia treatment and beyond.
Ruoff C; Cao M; Guilleminault C
Curr Pharm Des; 2011; 17(15):1476-82. PubMed ID: 21476951
[TBL] [Abstract][Full Text] [Related]
13. Suvorexant: a dual orexin receptor antagonist for the treatment of sleep onset and sleep maintenance insomnia.
Patel KV; Aspesi AV; Evoy KE
Ann Pharmacother; 2015 Apr; 49(4):477-83. PubMed ID: 25667197
[TBL] [Abstract][Full Text] [Related]
14. Orexin receptor antagonism, a new sleep-enabling paradigm: a proof-of-concept clinical trial.
Hoever P; Dorffner G; Beneš H; Penzel T; Danker-Hopfe H; Barbanoj MJ; Pillar G; Saletu B; Polo O; Kunz D; Zeitlhofer J; Berg S; Partinen M; Bassetti CL; Högl B; Ebrahim IO; Holsboer-Trachsler E; Bengtsson H; Peker Y; Hemmeter UM; Chiossi E; Hajak G; Dingemanse J
Clin Pharmacol Ther; 2012 Jun; 91(6):975-85. PubMed ID: 22549286
[TBL] [Abstract][Full Text] [Related]
15. An Update on Dual Orexin Receptor Antagonists and Their Potential Role in Insomnia Therapeutics.
Janto K; Prichard JR; Pusalavidyasagar S
J Clin Sleep Med; 2018 Aug; 14(8):1399-1408. PubMed ID: 30092886
[TBL] [Abstract][Full Text] [Related]
16. The Discovery of Suvorexant, the First Orexin Receptor Drug for Insomnia.
Coleman PJ; Gotter AL; Herring WJ; Winrow CJ; Renger JJ
Annu Rev Pharmacol Toxicol; 2017 Jan; 57():509-533. PubMed ID: 27860547
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological advances in the treatment of insomnia.
Richey SM; Krystal AD
Curr Pharm Des; 2011; 17(15):1471-5. PubMed ID: 21476952
[TBL] [Abstract][Full Text] [Related]
18. Orexin Receptor Antagonists: New Therapeutic Agents for the Treatment of Insomnia.
Roecker AJ; Cox CD; Coleman PJ
J Med Chem; 2016 Jan; 59(2):504-30. PubMed ID: 26317591
[TBL] [Abstract][Full Text] [Related]
19. A Comprehensive Review of Daridorexant, a Dual-Orexin Receptor Antagonist as New Approach for the Treatment of Insomnia.
Ziemichód W; Grabowska K; Kurowska A; Biała G
Molecules; 2022 Sep; 27(18):. PubMed ID: 36144776
[TBL] [Abstract][Full Text] [Related]
20. Orexin receptors: pharmacology and therapeutic opportunities.
Scammell TE; Winrow CJ
Annu Rev Pharmacol Toxicol; 2011; 51():243-66. PubMed ID: 21034217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
